Patent intelligence · US
US 8450339
Compositions for treatment of common cold
Compositions for treatment of common cold
Patent details — US 8450339
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2013
- Expiration
- May 23, 2033
- Applicant
- Takeda Pharma A/S
- Claims
- 23
- CPC classes
- A61K, A61K31/415, A61K31/46, A61P
Quick answer
US 8450339 (Compositions for treatment of common cold) is held by Takeda Pharma A/S. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharma A/S
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K31/415, A61K31/46, A61P, A61P11/00, A61P11/02
More from Takeda Pharma A/S
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8450339?
US 8450339 (Compositions for treatment of common cold) is held by Takeda Pharma A/S. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8450339?
Takeda Pharma A/S is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8450339 expire?
Our index shows an expiration date of May 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.